Arbutus Biopharma (ABUS) Net Cash Flow Growth (3y) (2016 - 2026)
Arbutus Biopharma (ABUS) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arbutus Biopharma | 880.36 Mn | 785.13 Mn | - | -16.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.47% |
| Dec 31, 2025 | -38.37% |
| Sep 30, 2025 | 13.67% |
| Jun 30, 2025 | 26.19% |
| Mar 31, 2025 | 26.55% |
| Dec 31, 2024 | -47.60% |
| Sep 30, 2024 | -38.56% |
| Jun 30, 2024 | 34.00% |
| Mar 31, 2024 | -14.80% |
| Dec 31, 2023 | 29.96% |
| Sep 30, 2023 | -29.85% |
| Jun 30, 2023 | -38.99% |
| Mar 31, 2023 | 56.36% |
| Dec 31, 2022 | 28.39% |
| Sep 30, 2022 | -59.71% |
| Jun 30, 2022 | -87.57% |
| Mar 31, 2022 | -37.42% |
| Dec 31, 2021 | 4.11% |
| Sep 30, 2021 | 59.25% |
| Jun 30, 2021 | -194.01% |